OPEX® Introduces the Next Generation in Goods-to-Person Warehouse Automation Technology - Infinity™ ASRS
28.3.2022 13:00:00 EEST | Business Wire | Press release
OPEX® Corporation, a global leader in warehouse automation technology, has added an innovative, industry-leading goods-to-person (G2P) solution to its Warehouse Automation portfolio.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220328005036/en/
The Infinity Goods-to-Person (G2P) solution (Photo: Business Wire)
The Infinity™ solution combines unparalleled storage density, configurability, and flexibility to meet the most pressing warehouse automation challenges for companies handling micro-fulfillment, omni-channel distribution, store replenishment, and ecommerce.
“Our focus is on engineering exciting new solutions that address unmet and evolving customer needs,” said Alex Stevens, President, OPEX Warehouse Automation. “The Infinity solution represents the next generation of goods-to-person technology to perfectly complement our existing Warehouse Automation product line.”
Automated G2P technology delivers the right item or SKU at the right time to the right operator or workstation, increasing productivity, throughput, and labor utilization by eliminating wasted time.
Powered by OPEX’s proprietary Cortex™ software platform, the Infinity G2P solution is engineered for maximum flexibility and scalability in both throughput and storage. Key benefits include reducing labor while increasing efficiency, storage density, and configurability.
Wireless Infinity iBOT® robotic vehicles access all inventory and port stations, moving freely underneath and throughout the system with no wasted mechanical motion, saving time and costs. Infinity iBOT robots are easily scalable by adding more iBOTs, presentation ports, and grids.
Unlike other competitive systems, the Infinity solution offers up to 35 percent more storage capacity with bot paths that are up to 65 percent more efficient.
The Infinity goods-to-person system utilizes a unique interlocking system to store totes triple-deep, eliminating wasted space and maximizing storage density. A configurable rack design optimizes warehouse space despite obstructions that may exist, such as columns or other equipment. The Infinity system’s flexibility also accommodates varied workflows and layouts.
The innovative Infinity solution was unveiled today at MODEX 2022, the industry’s premier material handling expo that showcases the latest in manufacturing and supply chain technology.
“Ecommerce is growing exponentially,” said Stevens. “Companies today need dependable yet advanced technology, the resiliency to meet shifting and seasonal demands, fast and accurate fulfillment, the ability to maximize space, and a partner they can trust. OPEX and the Infinity solution deliver all of this and more.”
Founded in 1973, OPEX brings generations of industry expertise and a proven track record developing first-class automation capabilities. The company is vertically integrated—innovating, engineering, manufacturing, selling, and servicing all of its automated solutions. This translates to the highest degree of quality equipment, reliable operations, product longevity, and an exceptional client experience.
The Infinity solution joins the existing Warehouse Automation portfolio at OPEX, which includes Sure Sort®—the industry-leading, high-speed, small-item robotic sorting system; and Perfect Pick®, a robotic goods-to-person picking solution that dramatically improves speed, efficiency, and reliability. All three solutions are custom configured for each client and designed to completely transform supply chain infrastructure.
To learn more, please visit warehouseautomation.com.
About OPEX
OPEX Corporation is a global leader in Next Generation Automation, providing innovative, unique solutions for warehouse, document and mail automation. With headquarters in Moorestown, NJ, USA—and facilities in Pennsauken, NJ; Plano, TX; France; Germany; Switzerland; the United Kingdom; and Australia—OPEX has more than 1,500 employees who are continuously reimagining and delivering customized, scalable technology solutions that solve the business challenges of today and the future.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220328005036/en/
Contact information
Colleen Ciak
cciak@opex.com
+1 856.727.1100, ext. 5350
+1 856.912.4952 Cell
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Otovo Hits 30,000 Customers in Under a Year, Tackling the Growing ‘Solar Service Crisis’21.5.2026 17:25:00 EEST | Press release
Otovo ASA (“Otovo”), a leading global energy service provider for residential and commercial customers, today announced it has reached 30,000 customers across the U.S. and Europe. A total of 20,000 customers have enrolled in Otovo Care, the Company’s membership-based home and commercial energy service, which is powered by Otovo’s industry-leading AI platform, Endurance™. “Reaching 30,000 customers in less than year is proof positive that home and business owners value their power systems,” said William J. (John) Berger, CEO of Otovo. “The ‘solar service crisis’ that is leaving millions of orphaned energy systems without support is driving strong interest in our Otovo Care membership program. Every day your home or commercial power system is not working, you are throwing money away. Otovo’s rapid response service platform keeps you up and running, ensuring your investment is delivering.” The rapid growth of the residential solar market created a growing population of “orphaned” solar sy
Carnegie Mellon University and Cleveland Clinic Develop AI System to Interpret Cardiac MRI Scans with Enhanced Accuracy21.5.2026 15:05:00 EEST | Press release
A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521762286/en/ A team of researchers from Carnegie Mellon University, in collaboration with Cleveland Clinic’s Cardiovascular Innovation Research Center, has developed an artificial intelligence (AI) system capable of interpreting some of the most complex heart scans in medicine, cardiac magnetic resonance imaging (MRI), without the need for manually labeled training data. The novel system, called CMR-CLIP, is designed to interpret cardiac MRI scans by connecting moving images of the heart with corresponding clinical radio
The Live Moment Effect: Genius Sports and MediaScience Study Finds Specific Moments in Live Sports Can Double Unaided Brand Recall21.5.2026 15:00:00 EEST | Press release
Genius Sports Limited (NYSE: GENI), a global leader in real-time sports data, today released new biometric research conducted with MediaScience showing that ads delivered immediately after emotionally heightened moments in live sports can double unaided brand recall. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521475265/en/ The Live Moment Effect report from Genius Sports and MediaScience. The study, The Live Moment Effect, finds that advertising effectiveness is significantly influenced by a viewer’s emotional state immediately before an ad is shown. In controlled biometric testing, ads shown after high-intensity sporting moments, such as near-scoring plays or crucial momentum shifts, delivered approximately double the unaided brand recall of baseline conditions. The Moment Before the Ad Matters The research challenges long-held assumptions about media value, showing that not all impressions are equal. Live sports rem
Merck Announces First Patient Dosed in Phase 3 Study for Investigational Antibody-Drug Conjugate in Colorectal Cancer21.5.2026 15:00:00 EEST | Press release
Merck, a leading science and technology company, today announced that the first patient has been dosed in the Phase 3 PROCEADE®-CRC-03 trial (NCT07549412). The study is evaluating precemtabart tocentecan (Precem‑TcT), a potential first‑in‑class investigational anti‑CEACAM5 antibody‑drug conjugate (ADC), for the treatment of metastatic colorectal cancer (mCRC). “Leveraging our novel payload‑linker technology, Precem‑TcT is the first CEACAM5‑targeted ADC in clinical studies with an exatecan payload, rationally designed for stability and enhanced cancer cell killing activity,” said David Weinreich, MD, MBA, Global Head of R&D and Chief Medical Officer for the Healthcare business of Merck. “The Phase 3 study and the enrollment of the first patient with Precem-TcT build on the Company’s more than 20 years of expertise in colorectal cancer, and highlight our commitment to advancing differentiated ADCs for heavily pretreated patients with limited treatment options.” The PROCEADE®-CRC-03 study
Baszucki Group Funds Oxford University Clinical Trial of Ketogenic Therapy for Early Psychosis21.5.2026 14:00:00 EEST | Press release
Baszucki Group today announced a £1.17 million grant to support a randomized controlled trial at the University of Oxford assessing the feasibility, safety, and efficacy of a ketogenic diet for patients at clinical high risk of psychosis (CHR-P). Researchers will test this nutritional therapy's ability to improve patients' mental and physical health. This project builds on a growing body of research suggesting the potential of metabolic therapies in treating serious mental illness. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260521877110/en/ Baszucki Group Funds £1.17 Million for University of Oxford Trial of Ketogenic Therapy for Early Psychosis Psychotic disorders carry a massive personal burden and are associated with a lower life expectancy. Psychosis does not develop immediately, but typically emerges following a period of early, subtle symptoms. Individuals in this stage, classified as CHR-P, represent a critical pr
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom